Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients

Breast cancer (BC) categorized as human epidermal growth factor receptor 2 (HER2) borderline [2+ by immunohistochemistry (IHC 2+)] presents challenges for the testing, frequently obscured by intratumoral heterogeneity (ITH). This leads to difficulties in therapy decisions. We aimed to establish prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Radziuviene, Gedmante, Rasmusson, Allan, Augulis, Renaldas, Grineviciute, Ruta Barbora, Zilenaite, Dovile, Laurinaviciene, Aida, Ostapenko, Valerijus, Laurinavicius, Arvydas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631965/
https://www.ncbi.nlm.nih.gov/pubmed/34858854
http://dx.doi.org/10.3389/fonc.2021.774088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631965/
https://www.ncbi.nlm.nih.gov/pubmed/34858854
http://dx.doi.org/10.3389/fonc.2021.774088

Ejemplares similares